Trial reportSchizophrenia bulletin2013
P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.
Trial report in Schizophrenia bulletin, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication.Schizophrenia bulletin · 2014Trial
- Prepulse Inhibition and P50 Suppression in Relation to Creativity and Attention: Dispersed Attention Beneficial to Quantitative but Not Qualitative Measures of Divergent Thinking.Frontiers in psychiatry · 2022Article
- Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Dysfunction of Inferior Parietal Lobule During Sensory Gating in Patients With Amnestic Mild Cognitive Impairment.Frontiers in aging neuroscience · 2020Article
- Autism: a transdiagnostic, dimensional, construct of reasoning?The European journal of neuroscience · 2018Review
- Electrophysiological Evidence in Schizophrenia in Relation to Treatment Response.Frontiers in psychiatry · 2018Review
- Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.Neuroscience and biobehavioral reviews · 2017Review
- Amygdalar Gating of Early Sensory Processing through Interactions with Locus Coeruleus.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Article
- Comparing Pharmacological Modulation of Sensory Gating in Healthy Humans and Rats: The Effects of Reboxetine and Haloperidol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Article
- Association Study of CHRNA7 Promoter Variants with Sensory and Sensorimotor Gating in Schizophrenia Patients and Healthy Controls: A Danish Case-Control Study.Neuromolecular medicine · 2015Article
- Different P50 sensory gating measures reflect different cognitive dysfunctions in schizophrenia.Schizophrenia research. Cognition · 2015Article
- Progressive reduction of visual P300 amplitude in patients with first-episode schizophrenia: an ERP study.Schizophrenia bulletin · 2015Article
- Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Article
- Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Article
- Differential effects of estrogen and testosterone on auditory sensory gating in rats.Psychopharmacology · 2014Article
- Abnormal auditory sensory gating-out in first-episode and never-medicated paranoid schizophrenia patients: an fMRI study.Experimental brain research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNumerous studies have demonstrated sensory gating deficits in schizophrenia. However, only a few longitudinal studies report on the effects of antipsychotic treatment on sensory gating deficits and their results are inconsistent. In the present study, P50 suppression and its neural generators were investigated in antipsychotic-naïve first-episode patients with schizophrenia before and after 6 months of treatment with quetiapine.
methodsThirty-four antipsychotic-naïve first-episode schizophrenia patients and age and gender matched healthy controls were tested in an auditory sensory gating paradigm at baseline and after 6 months. During this period, the patients were treated with quetiapine, while controls received no treatment. Sixteen patients completed the study.
resultsPatients showed significant reduced P50 suppression compared with controls at baseline but not at follow-up. Furthermore, a significant positive correlation between baseline P50 suppression and dose of quetiapine at follow-up was found. P50 suppression in patients receiving above median dosages of quetiapine increased significantly from baseline to follow-up. At baseline, a frontocentral source was significantly more active in patients than in controls at the time of the testing stimulus.
conclusionsThe present findings suggest that P50 suppression deficits are already present at an early stage of schizophrenia. Furthermore, particularly those patients with more severe gating deficits appeared to need higher dosages of quetiapine, although their clinical symptoms did not seem to indicate this. Quetiapine treatment significantly improved these gating deficits. Furthermore, a frontocentral source in the brain appeared to be involved in the deficient P50 gating of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.